Poland· PL-100479638

Almozen

A almotriptan product containing almotriptanum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC N02CC05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAlmozenATCN02CC05REGISTER NO.PL-100479638PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Almotriptan is registered in 16 of 19 countries.

Countries holding a registration under ATC N02CC05 (almotriptan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Almotriptan · ATC N02CC05

16 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of almotriptan costs, country by country.

Normalised to the WHO defined daily dose (12.5 mg), the median price runs from $1.25 in France to $6.02 in Switzerland — a ×4.8 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Almotriptan · price per daily dose (12.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$6.02
  • ES Spain$5.56
  • IT Italy$3.29
  • FR France$1.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Almotriptanum
Manufacturer
InPharm Sp. z o.o.
Country
Poland (PL)
ATC code
N02CC05
ATC class
Almotriptan
Defined daily dose
12.5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991507855
  • gtin
    05909991507862

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for almotriptan.

Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Almotriptan · interactions on record

81 records

  • 13 severe
  • 29 moderate
  • 38 info

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Almotriptan in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All almotriptan products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Belgium · Almogran
  • Germany · Almogran, Almotriptan Bei Migräne Heumann
  • Spain · Almogran, Almotriptán Cinfa
  • Finland · Almogran
  • France · Almogran, Almotriptan Biogaran
  • United Kingdom (Northern Ireland) · Almogran, Almotriptan Accord-Uk
  • Greece · Almogran
  • Ireland · Almogran
  • Italy · Almogran, Almotrex
  • Luxembourg · Almogran
  • Netherlands · Almogran
  • Norway · Almogran, Almotriptan Orifarm
  • Portugal · Almogran, Almotriptano Galenicum
  • Sweden · Almogran, Almotriptan Orifarm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/770c26d9-7cd4-4c84-85e3-5cb93914e538
GET /v1/drugs/770c26d9-7cd4-4c84-85e3-5cb93914e538?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "12,5 mg",
  "packaging": "05909991507855 ¦ Rp ¦ 148948\n3 tabl.\n05909991507862 ¦ Rp ¦ 148949\n6 tabl.",
  "substance": "Almotriptanum 12.5 mg",
  "common_name": "Almotriptanum",
  "pl_product_id": "100479638",
  "pozwolenie_nr": "020/23",
  "auth_procedure": "IR",
  "authorisation_validity": "2028-02-14"
}

See everything about almotriptan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.